Maxime Fayon

Title: Maxime Fayon: Innovator in Antibody Development

Introduction

Maxime Fayon is a prominent inventor based in Paris, France. He has made significant contributions to the field of immunotherapy, particularly in the development of antibodies targeting CD38. His innovative work has the potential to transform treatment options for patients with malignant hematological diseases, including multiple myeloma.

Latest Patents

Maxime Fayon holds a patent for "Antibodies having specificity for CD38 and uses thereof." This invention focuses on a new antibody against CD38, which is expressed in various malignant hematological diseases. The patent describes the development of Bi38-3, a bispecific T cell engager that targets CD38 on multiple myeloma cells. Bi38-3 effectively recruits cytotoxic T cells, triggering their proliferation and the release of cytokines, leading to the lysis of CD38 positive multiple myeloma cells in vitro. Importantly, Bi38-3 has shown efficacy in reducing tumor cells in a xenograft mouse model of human multiple myeloma.

Career Highlights

Throughout his career, Maxime Fayon has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université de Paris. His research has focused on developing innovative therapeutic strategies to combat malignant diseases, showcasing his commitment to advancing medical science.

Collaborations

Maxime has collaborated with notable professionals in his field, including Armand Bensussan and Jean-Christophe Bories. These collaborations have contributed to the success of his research and the development of groundbreaking therapies.

Conclusion

Maxime Fayon's work in antibody development represents a significant advancement in the treatment of malignant hematological diseases. His innovative approaches and dedication to research continue to pave the way for new therapeutic options for patients.